Wegovy recommendation lifts Novo Nordisk shares as NHS access widens

Britain's health technology assessment body, the National Institute for Health and Care Excellence (NICE), has recommended semaglutide (marketed as Wegovy) for use to reduce the risk of recurrent heart attacks and strokes in a broader group of patients, and Novo Nordisk shares moved higher following the announcement.

According to NICE's 1 April 2026 statement, the recommendation covers adults who have previously suffered a heart attack, stroke or peripheral arterial disease and who have a body mass index (BMI) of at least 27 kg/m². The guidance cites results from the SELECT trial, in which roughly 17,600 participants receiving semaglutide had a near 20% lower risk of major cardiovascular events versus placebo; NICE estimates about 1.2 million people could be eligible under this indication. The agency judged the treatment provides value for the NHS.

Markets reacted quickly: Novo Nordisk's share price showed an uptick in morning trading as investors priced in an expanded addressable patient population and potential revenue upside from the new cardiovascular indication. The move also reflects sentiment that the drug’s benefits extend beyond weight loss, supporting broader clinical use. That said, the company has recently faced intense pricing pressure and competitive headwinds that have contributed to volatility in its stock, tempering some investor enthusiasm.

From a policy and health-economics perspective, extending access on the NHS carries implications for procurement budgets, specialist service capacity and long-term cost-effectiveness calculations. NICE’s appraisal and the NHS’s subsequent implementation decisions will influence how quickly and at what scale semaglutide is adopted for secondary prevention, while also shaping international reimbursement debates about GLP-1 class medicines.

Analysts say the NICE recommendation is a clear near-term positive for Novo Nordisk but caution that structural challenges remain: pricing negotiations, potential loss of exclusivity in some markets and competitive launches could offset revenue gains. Market watchers will monitor uptake data, NHS commissioning timetables and any commercial arrangements that affect net prices; these factors will determine whether today’s market reaction translates into sustained value for shareholders.